Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9,159 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer.
Tsurutani J, Hara F, Kitada M, Takahashi M, Kikawa Y, Kato H, Sakata E, Naito Y, Hasegawa Y, Saito T, Iwasa T, Taira N, Takashima T, Kashiwabara K, Aihara T, Mukai H. Tsurutani J, et al. Among authors: kato h. Breast. 2021 Feb;55:63-68. doi: 10.1016/j.breast.2020.12.002. Epub 2020 Dec 9. Breast. 2021. PMID: 33341707 Free PMC article. Clinical Trial.
Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer.
Taira N, Kashiwabara K, Tsurutani J, Kitada M, Takahashi M, Kato H, Kikawa Y, Sakata E, Naito Y, Hasegawa Y, Saito T, Iwasa T, Takashima T, Aihara T, Mukai H, Hara F. Taira N, et al. Among authors: kato h. Breast Cancer. 2022 Jan;29(1):131-143. doi: 10.1007/s12282-021-01290-5. Epub 2021 Sep 7. Breast Cancer. 2022. PMID: 34491513 Free PMC article. Clinical Trial.
Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer.
Taira N, Kashiwabara K, Tsurutani J, Kitada M, Takahashi M, Kato H, Kikawa Y, Sakata E, Naito Y, Hasegawa Y, Saito T, Iwasa T, Takashima T, Aihara T, Mukai H, Hara F. Taira N, et al. Among authors: kato h. Breast Cancer. 2022 Jan;29(1):186-188. doi: 10.1007/s12282-021-01296-z. Breast Cancer. 2022. PMID: 34562260 Free PMC article. No abstract available.
[Structural Pharmacology for Receptors and Transporters].
Shimizu T, Kato H. Shimizu T, et al. Among authors: kato h. Yakugaku Zasshi. 2016;136(2):171-2. doi: 10.1248/yakushi.15-00229-F. Yakugaku Zasshi. 2016. PMID: 26831788 Free article. Japanese. No abstract available.
Evaluation of the COVID-19 diagnostic performance of Rapiim SARS-CoV-2-H, the highly sensitive SARS-CoV-2 antigen qualitative test kit.
Okumura N, Kato H, Yamamoto K, Hagiwara E, Kurokawa M, Hikida S, Maruki T, Mezaki K, Tanaka K, Ogura T, Ohmagari N. Okumura N, et al. Among authors: kato h. Diagn Microbiol Infect Dis. 2024 Nov 7;111(1):116598. doi: 10.1016/j.diagmicrobio.2024.116598. Online ahead of print. Diagn Microbiol Infect Dis. 2024. PMID: 39546837 Free article.
9,159 results